Minoxidil 10 mg is an oral minoxidil tablet manufactured by Dragon Pharma, dosed at 10 mg per tablet in a 100-tablet package.
Minoxidil 10 mg contains minoxidil, a direct-acting peripheral vasodilator. Minoxidil works by opening ATP-modulated potassium channels in vascular smooth muscle, causing hyperpolarization and relaxation of the smooth muscle, which leads to vasodilation and reduced blood pressure. In medical practice, oral minoxidil is indicated for severe hypertension that has not responded to other medications, typically in combination with a diuretic and a beta-blocker to manage reflex tachycardia and fluid retention.
Minoxidil is unique among antihypertensives for its common side effect of hypertrichosis—excessive hair growth on the face, arms, back, and legs. This observation led to the development of topical minoxidil for hair loss, which became the first FDA-approved topical treatment for androgenetic alopecia. More recently, low-dose oral minoxidil has gained significant interest as an off-label treatment for hair loss, with multiple published studies supporting its efficacy and safety at doses of 2.5 mg to 5 mg daily.
In non-medical bodybuilding contexts, oral minoxidil is occasionally referenced for hair loss prevention during cycles involving androgenic compounds. However, the 10 mg strength far exceeds the typical doses used for hair loss management, and the cardiovascular effects of minoxidil at this dose are significant. The 10 mg strength of Minoxidil 10 mg allows for splitting to achieve the lower doses commonly referenced for hair growth applications.
Minoxidil 10 mg is supplied as an oral tablet containing 10 mg of minoxidil per tablet. Oral administration allows for convenient dosing and flexible dose adjustment through tablet splitting.
Minoxidil is a potent oral vasodilator that lowers blood pressure through potassium channel activation and promotes hair growth through mechanisms that are not fully characterized.
Minoxidil belongs to the class of direct-acting peripheral vasodilators. Its primary mechanism involves the activation of ATP-modulated potassium channels in vascular smooth muscle. This causes potassium efflux, membrane hyperpolarization, and relaxation of the smooth muscle, resulting in vasodilation. The reduced peripheral resistance leads to decreased blood pressure, but also triggers compensatory mechanisms including reflex tachycardia and fluid retention.
The pharmacokinetics of minoxidil are well characterized. After oral administration, over 90% of the drug is absorbed, and peak plasma levels are achieved within 3 to 4 hours. The average plasma half-life in humans is approximately 4 hours. Minoxidil undergoes extensive first-pass metabolism in the liver, primarily through conjugation with glucuronic acid. The parent molecule is converted to minoxidil-N-O-sulfate, which is believed to be the active metabolite responsible for both the vasodilatory and hair growth effects.
The hair growth effect of minoxidil was discovered incidentally during clinical trials for hypertension, where hypertrichosis was observed in a significant proportion of patients. The mechanism of hair growth promotion is not completely understood but is thought to involve enhanced microcirculation around hair follicles, direct stimulation of follicular cells, and prolongation of the anagen (growing) phase of the hair cycle.
Minoxidil has a relatively short plasma half-life of approximately 4 hours. This supports the multiple daily dosing regimens commonly referenced in clinical and non-medical contexts.
Dragon Pharma offers a range of compounds relevant to managing side effects during cycles. Minoxidil 10 mg is positioned as a vasodilator with hair growth applications, complementing other ancillary products.
For hair loss specifically, some individuals consider a combined strategy with oral minoxidil and a 5-alpha-reductase inhibitor such as Finasteride, which addresses the hormonal component of androgenetic alopecia. For topical applications, Minoxidil is also available as a topical solution. For other cycle support needs, Dragon Pharma offers Arimidex and Aromasin for estrogen management.
Published laboratory reports for Minoxidil 10 mg are shown below with the test date, measured content and percentage of the product's 10 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
The information below is provided for educational reference only. Minoxidil is a prescription medication for severe hypertension; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In medical practice, oral minoxidil for hypertension is typically initiated at 5 mg daily and titrated up to 10 to 40 mg daily, usually in divided doses, with a diuretic and beta-blocker to manage side effects. In non-medical bodybuilding contexts, minoxidil is occasionally referenced at 2.5–5 mg daily for hair loss prevention, though the 10 mg strength exceeds the typical doses used for this purpose and requires splitting. Such use falls outside approved medical indications.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (hypertension) | 5–40 mg | Once daily or divided |
| Hair loss (non-medical) | 2.5–5 mg | Once daily |
| Bodybuilding hair support | 2.5 mg | Once daily |
Minoxidil 10 mg tablets may require splitting to achieve the lower doses commonly referenced for hair loss applications.
Minoxidil is not an anabolic compound and is not stacked for muscle-building purposes. It is occasionally referenced in bodybuilding contexts as part of a hair preservation strategy during cycles involving androgenic compounds. A combined approach with a 5-alpha-reductase inhibitor such as Finasteride is sometimes discussed, as the two agents address different aspects of androgenetic alopecia.
For individuals using topical minoxidil, Dragon Pharma offers Minoxidil as a topical solution. For other cycle support needs, Arimidex and Aromasin are commonly referenced for estrogen management.
At oral doses used for hypertension, minoxidil can cause significant fluid retention, reflex tachycardia, and pericardial effusion. At the lower doses referenced for hair loss, side effects are generally milder and may include hypertrichosis, mild ankle edema, and a small increase in resting heart rate.
Minoxidil is a potent vasodilator and can cause hypotension if used at higher doses without appropriate monitoring. Blood pressure and heart rate should be monitored during use, particularly when initiating or adjusting the dose.
Minoxidil is not part of standard post-cycle therapy protocols, which focus on restoring endogenous testosterone production. PCT compounds such as Clomid and Nolvadex address the hypothalamic-pituitary-gonadal axis rather than vasodilation or hair growth. Minoxidil's role is generally limited to on-cycle hair preservation strategies.
Dosing strategies and support protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Minoxidil is a potent vasodilator that can affect cardiovascular and renal function. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Oral minoxidil is indicated only for severe hypertension that has not responded to other medications. It is typically administered with a diuretic to manage fluid retention and a beta-blocker to control reflex tachycardia. Minoxidil should be taken only under medical supervision and never shared with others.
Non-medical use of minoxidil for hair loss during performance-enhancement cycles is not approved by regulatory agencies and may carry additional health risks. Product quality does not establish that non-medical use is safe or appropriate.
Minoxidil at oral doses used for hypertension can cause serious adverse effects including fluid and salt retention, pericardial effusion, pericarditis, and tamponade. Reflex tachycardia is common and may require management with a beta-blocker. Hypertrichosis occurs in a significant proportion of patients.
At lower doses used for hair loss, side effects are generally milder. Commonly reported effects include hypertrichosis (excessive hair growth on face and body), mild ankle edema, and a small increase in resting heart rate. These effects are typically dose-dependent and reversible upon discontinuation.
Minoxidil can cause allergic reactions including rash, itching, and swelling. Visual disturbances have been reported in rare cases. Individuals with a history of cardiovascular disease or renal impairment should be evaluated before use.
Minoxidil is contraindicated in individuals with hypersensitivity to minoxidil. It should be used with caution in patients with coronary artery disease, cerebrovascular disease, or heart failure. Pre-treatment evaluation of cardiac function and renal function is recommended for oral use.
Medically supervised oral minoxidil therapy typically involves regular monitoring of blood pressure, heart rate, weight, and renal function. Fluid retention should be assessed through weight monitoring and evaluation for edema. At lower doses used for hair loss, periodic heart rate and blood pressure checks are commonly referenced.
Keep the product securely stored and protected from conditions that could compromise the tablets or packaging. Inspect the product before use and do not use if it appears damaged or otherwise abnormal. Keep all medications out of the reach of children.
Minoxidil 10 mg is supplied through the official Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
To verify your Minoxidil 10 mg product, use the security code on the packaging and cross-check it on the Dragon Pharma official site. Official Dragon Pharma presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Proper storage conditions help preserve tablet integrity and stability throughout shelf life.
Store in a cool, dry place at controlled room temperature (15–25°C). Protect from excessive heat, moisture, and direct light. Keep the tablets in their original packaging until use.
Do not use if the packaging appears damaged or if the tablets show signs of deterioration. Keep out of reach of children.
Answers to common questions about Minoxidil 10 mg, minoxidil, hair growth, product strength and laboratory testing.
Minoxidil 10 mg contains minoxidil, a vasodilator. In medical practice, oral minoxidil is used for severe hypertension that has not responded to other medications. In non-medical bodybuilding contexts, it is occasionally referenced for hair loss prevention, though the 10 mg strength exceeds typical doses for this purpose. Such use falls outside approved medical indications.
In medical practice, oral minoxidil for hypertension is typically dosed once daily or divided, with a range of 5 to 40 mg daily. In non-medical bodybuilding contexts for hair loss, common reference points are 2.5 to 5 mg daily, which may require splitting the 10 mg tablet. Dosing should be individualized.
Minoxidil is not part of standard post-cycle therapy, which focuses on restoring endogenous testosterone production. PCT compounds like Clomid and Nolvadex address the hypothalamic-pituitary-gonadal axis rather than vasodilation. Minoxidil's role is generally limited to on-cycle hair preservation strategies.
Minoxidil opens potassium channels in vascular smooth muscle, causing vasodilation and reduced blood pressure. It also promotes hair growth through mechanisms that are not fully understood but may involve increased blood flow to hair follicles and prolongation of the growing phase of the hair cycle.
For hair growth, visible results from minoxidil typically require at least 3 to 4 months of consistent use. The hair cycle is slow, and early shedding may occur as follicles transition. Full effects may take 6 to 12 months to become apparent.
There is no single best treatment for hair loss. Minoxidil and Finasteride are the two most established options, but they work through different mechanisms. Minoxidil promotes blood flow and hair growth, while finasteride reduces DHT. Some individuals use both together for a combined approach.
Oral minoxidil is absorbed systemically and affects the entire body, which is why it can cause side effects like fluid retention and hypertrichosis. Topical Minoxidil is applied directly to the scalp and has minimal systemic absorption, reducing the risk of systemic side effects but potentially being less effective for some individuals.
Minoxidil and Finasteride address hair loss through different mechanisms. Minoxidil is a vasodilator that improves blood flow to hair follicles, while finasteride is a 5-alpha-reductase inhibitor that reduces DHT, the hormone primarily responsible for androgenetic alopecia. They are often used together for complementary effects.
Yes. In medical practice, 10 mg daily is a significant dose for hypertension and is typically used only when other medications have failed. For hair loss, doses of 2.5 to 5 mg daily are more commonly referenced. The 10 mg strength of Minoxidil 10 mg allows for splitting to achieve these lower doses.
Minoxidil 10 mg is labeled at 10 mg of minoxidil per tablet. It is supplied in a 100-tablet package, giving 1,000 mg of total labeled minoxidil content.
Yes. A published laboratory report dated July 12, 2024 measured Minoxidil 10 mg at 10.87 mg/tablet, equivalent to 108.7% of its 10 mg label claim. The batch number for this report was #HDMNX6. The complete report can be viewed in the Lab Reports tab.
Yes. An initial shedding phase is common in the first 2 to 8 weeks of minoxidil use. This occurs as hair follicles transition from the resting phase to the growing phase, pushing out older hairs. This shedding is temporary and typically resolves by month 3.